Oligonucleotides are short chain RNA or DNA typically made by using automated synthesizers. Oligonucleotides therapy is different from conventional medicine since it can inhibit the expression of specific genes and their development takes place with the raw chemical modified artificial nucleus acids. This lead to development of brand new oligonucleotides targeting certain genes and treating chronic diseases. They are broadly used in applications such as infectious diseases, oncology, kidney diseases, and cardiovascular diseases.
MARKET SCOPE
The "Global Oligonucleotide-Based Therapies Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oligonucleotide-based therapies market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading oligonucleotide-based therapies market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type, the global oligonucleotide-based therapies market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory and RNAi.
- On the basis of application, the market is bifurcated into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others.
MARKET DYNAMICS
Drivers
- Increasing incidence of cancer and infectious disease and the necessity for personalized medicines for neurodegenerative disorders is expected to drive the oligonucleotide-based therapies market.
- Increasing demand for novel therapies and growing innovative new oligonucleotides boosts the market growth.
- Rising licensing and collaboration activities and growing demand for advanced technologies in oligonucleotide therapeutics fuel the market growth.
Restraints
- The incapability to detect minor antibodies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oligonucleotide-based therapies market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the oligonucleotide-based therapies market in these regions.
IMPACT OF COVID-19 ON OLIGONUCLEOTIDE-BASED THERAPIES MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. With the outbreak of pandemic, a slight decrease in the oligonucleotide-based drugs sales was seen due to worldwide restrictions and lockdown imposed during the COVID-19 pandemic. However, the pharmaceutical and biopharmaceutical companies, along with the players of the oligonucleotide market, came forward to contribute to research efforts worldwide by providing oligo products. These products were used for development of test kits, treatments, and vaccines that target the novel coronavirus infection. The various initiatives by the market players and usage of a wide range of oligonucleotide products like probes and primers in coronavirus research has helped researchers gain a better insight of the virus. Hence, the oligonucleotide market is estimated to witness growth in coming years.
Have a question?
Akshay
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oligonucleotide-based therapies market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the oligonucleotide-based therapies market in these regions.
IMPACT OF COVID-19 ON OLIGONUCLEOTIDE-BASED THERAPIES MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. With the outbreak of pandemic, a slight decrease in the oligonucleotide-based drugs sales was seen due to worldwide restrictions and lockdown imposed during the COVID-19 pandemic. However, the pharmaceutical and biopharmaceutical companies, along with the players of the oligonucleotide market, came forward to contribute to research efforts worldwide by providing oligo products. These products were used for development of test kits, treatments, and vaccines that target the novel coronavirus infection. The various initiatives by the market players and usage of a wide range of oligonucleotide products like probes and primers in coronavirus research has helped researchers gain a better insight of the virus. Hence, the oligonucleotide market is estimated to witness growth in coming years.
MARKET PLAYERS
The report covers key developments in the oligonucleotide-based therapies market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from oligonucleotide-based therapies market are anticipated to have lucrative growth opportunities in the future with the rising demand for oligonucleotide-based therapies in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oligonucleotide-based therapies market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- PCI Biotech
- SomaGenics
- InteRNA Technologies
- Frontiers
- miRagen Therapeutics, Inc.
- Ionis Pharmaceuticals, Inc.
- Aligos Therapeutics
- Gilead Sciences, Inc.
- Biogen Inc.
- Regulus Therapeutics Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oligonucleotide-based Therapies Market - By Type
1.3.2 Oligonucleotide-based Therapies Market - By Application
1.3.3 Oligonucleotide-based Therapies Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. OLIGONUCLEOTIDE-BASED THERAPIES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - GLOBAL MARKET ANALYSIS
6.1. OLIGONUCLEOTIDE-BASED THERAPIES - GLOBAL MARKET OVERVIEW
6.2. OLIGONUCLEOTIDE-BASED THERAPIES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTISENSE
7.3.1. Overview
7.3.2. Antisense Market Forecast and Analysis
7.4. RIBOZYMES
7.4.1. Overview
7.4.2. Ribozymes Market Forecast and Analysis
7.5. APTAMERS
7.5.1. Overview
7.5.2. Aptamers Market Forecast and Analysis
7.6. MIRNA
7.6.1. Overview
7.6.2. Mirna Market Forecast and Analysis
7.7. CPG/IMMUNOSTIMULATORY
7.7.1. Overview
7.7.2. CPG/Immunostimulatory Market Forecast and Analysis
7.8. RNAI.
7.8.1. Overview
7.8.2. RNAi. Market Forecast and Analysis
8. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. INFECTIOUS DISEASES
8.3.1. Overview
8.3.2. Infectious Diseases Market Forecast and Analysis
8.4. ONCOLOGY
8.4.1. Overview
8.4.2. Oncology Market Forecast and Analysis
8.5. NEURODEGENERATIVE DISORDERS
8.5.1. Overview
8.5.2. Neurodegenerative Disorders Market Forecast and Analysis
8.6. CARDIOVASCULAR DISEASES
8.6.1. Overview
8.6.2. Cardiovascular Diseases Market Forecast and Analysis
8.7. KIDNEY DISEASES
8.7.1. Overview
8.7.2. Kidney Diseases Market Forecast and Analysis
8.8. OTHERS.
8.8.1. Overview
8.8.2. Others. Market Forecast and Analysis
9. OLIGONUCLEOTIDE-BASED THERAPIES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Oligonucleotide-based Therapies Market Overview
9.1.2 North America Oligonucleotide-based Therapies Market Forecasts and Analysis
9.1.3 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.1.4 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.1.5 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Oligonucleotide-based Therapies Market
9.1.5.1.1 Canada Oligonucleotide-based Therapies Market by Type
9.1.5.1.2 Canada Oligonucleotide-based Therapies Market by Application
9.1.5.2 Mexico Oligonucleotide-based Therapies Market
9.1.5.2.1 Mexico Oligonucleotide-based Therapies Market by Type
9.1.5.2.2 Mexico Oligonucleotide-based Therapies Market by Application
9.1.5.3 US Oligonucleotide-based Therapies Market
9.1.5.3.1 US Oligonucleotide-based Therapies Market by Type
9.1.5.3.2 US Oligonucleotide-based Therapies Market by Application
9.2. EUROPE
9.2.1 Europe Oligonucleotide-based Therapies Market Overview
9.2.2 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis
9.2.3 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.2.4 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.2.5 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Oligonucleotide-based Therapies Market
9.2.5.1.1 Germany Oligonucleotide-based Therapies Market by Type
9.2.5.1.2 Germany Oligonucleotide-based Therapies Market by Application
9.2.5.2 France Oligonucleotide-based Therapies Market
9.2.5.2.1 France Oligonucleotide-based Therapies Market by Type
9.2.5.2.2 France Oligonucleotide-based Therapies Market by Application
9.2.5.3 Italy Oligonucleotide-based Therapies Market
9.2.5.3.1 Italy Oligonucleotide-based Therapies Market by Type
9.2.5.3.2 Italy Oligonucleotide-based Therapies Market by Application
9.2.5.4 Spain Oligonucleotide-based Therapies Market
9.2.5.4.1 Spain Oligonucleotide-based Therapies Market by Type
9.2.5.4.2 Spain Oligonucleotide-based Therapies Market by Application
9.2.5.5 United Kingdom Oligonucleotide-based Therapies Market
9.2.5.5.1 United Kingdom Oligonucleotide-based Therapies Market by Type
9.2.5.5.2 United Kingdom Oligonucleotide-based Therapies Market by Application
9.2.5.6 Rest of Europe Oligonucleotide-based Therapies Market
9.2.5.6.1 Rest of Europe Oligonucleotide-based Therapies Market by Type
9.2.5.6.2 Rest of Europe Oligonucleotide-based Therapies Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Oligonucleotide-based Therapies Market Overview
9.3.2 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis
9.3.3 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Oligonucleotide-based Therapies Market
9.3.5.1.1 Australia Oligonucleotide-based Therapies Market by Type
9.3.5.1.2 Australia Oligonucleotide-based Therapies Market by Application
9.3.5.2 China Oligonucleotide-based Therapies Market
9.3.5.2.1 China Oligonucleotide-based Therapies Market by Type
9.3.5.2.2 China Oligonucleotide-based Therapies Market by Application
9.3.5.3 India Oligonucleotide-based Therapies Market
9.3.5.3.1 India Oligonucleotide-based Therapies Market by Type
9.3.5.3.2 India Oligonucleotide-based Therapies Market by Application
9.3.5.4 Japan Oligonucleotide-based Therapies Market
9.3.5.4.1 Japan Oligonucleotide-based Therapies Market by Type
9.3.5.4.2 Japan Oligonucleotide-based Therapies Market by Application
9.3.5.5 South Korea Oligonucleotide-based Therapies Market
9.3.5.5.1 South Korea Oligonucleotide-based Therapies Market by Type
9.3.5.5.2 South Korea Oligonucleotide-based Therapies Market by Application
9.3.5.6 Rest of Asia-Pacific Oligonucleotide-based Therapies Market
9.3.5.6.1 Rest of Asia-Pacific Oligonucleotide-based Therapies Market by Type
9.3.5.6.2 Rest of Asia-Pacific Oligonucleotide-based Therapies Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Oligonucleotide-based Therapies Market Overview
9.4.2 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis
9.4.3 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Oligonucleotide-based Therapies Market
9.4.5.1.1 South Africa Oligonucleotide-based Therapies Market by Type
9.4.5.1.2 South Africa Oligonucleotide-based Therapies Market by Application
9.4.5.2 Saudi Arabia Oligonucleotide-based Therapies Market
9.4.5.2.1 Saudi Arabia Oligonucleotide-based Therapies Market by Type
9.4.5.2.2 Saudi Arabia Oligonucleotide-based Therapies Market by Application
9.4.5.3 U.A.E Oligonucleotide-based Therapies Market
9.4.5.3.1 U.A.E Oligonucleotide-based Therapies Market by Type
9.4.5.3.2 U.A.E Oligonucleotide-based Therapies Market by Application
9.4.5.4 Rest of Middle East and Africa Oligonucleotide-based Therapies Market
9.4.5.4.1 Rest of Middle East and Africa Oligonucleotide-based Therapies Market by Type
9.4.5.4.2 Rest of Middle East and Africa Oligonucleotide-based Therapies Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Oligonucleotide-based Therapies Market Overview
9.5.2 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis
9.5.3 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.5.4 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.5.5 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Oligonucleotide-based Therapies Market
9.5.5.1.1 Brazil Oligonucleotide-based Therapies Market by Type
9.5.5.1.2 Brazil Oligonucleotide-based Therapies Market by Application
9.5.5.2 Argentina Oligonucleotide-based Therapies Market
9.5.5.2.1 Argentina Oligonucleotide-based Therapies Market by Type
9.5.5.2.2 Argentina Oligonucleotide-based Therapies Market by Application
9.5.5.3 Rest of South and Central America Oligonucleotide-based Therapies Market
9.5.5.3.1 Rest of South and Central America Oligonucleotide-based Therapies Market by Type
9.5.5.3.2 Rest of South and Central America Oligonucleotide-based Therapies Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. OLIGONUCLEOTIDE-BASED THERAPIES MARKET, KEY COMPANY PROFILES
11.1. PCI BIOTECH
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SOMAGENICS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. INTERNA TECHNOLOGIES
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. FRONTIERS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MIRAGEN THERAPEUTICS, INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. IONIS PHARMACEUTICALS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ALIGOS THERAPEUTICS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. GILEAD SCIENCES, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. BIOGEN INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. REGULUS THERAPEUTICS INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. PCI Biotech
2. SomaGenics
3. InteRNA Technologies
4. Frontiers
5. miRagen Therapeutics, Inc.
6. Ionis Pharmaceuticals, Inc.
7. Aligos Therapeutics
8. Gilead Sciences, Inc.
9. Biogen Inc.
10. Regulus Therapeutics Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Oligonucleotide-based Therapies Market
Apr 2024
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Apr 2024
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Apr 2024
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Apr 2024
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
Apr 2024